Neurology Book

http://www.fpnotebook.com/

RivastigmineAka: Exelon

Advertisement

  1. See Also
    1. Tacrine (Cognex)
    2. Donepezil (Aricept)
  2. Indications
    1. Alzheimer's Disease related Dementia
  3. Mechanism
    1. Carbamate-based noncompetitive cholinesterase inhibitor
    2. Inhibits butyrylcholinesterase and acetylcholinesterase
    3. Increases cholinergic transmission
  4. Pharmacokinetics
    1. Peak: 1 hour
    2. Duration: 10 hours
  5. Drug Interactions
    1. No significant drug interactions
  6. Efficacy
    1. Modestly improves scores on neuropsychological tests
    2. Benefits decrease after 40 weeks of treatment
  7. Adverse Effects
    1. Nausea or Vomiting
    2. Diarrhea
    3. Abdominal Pain
    4. Anorexia
    5. Weight loss
    6. No hepatotoxicity risk (contrast with Tacrine)
  8. Dosing
    1. Initial: 1.5 mg PO bid with food
    2. Increase dose by 1.5 mg every 2 weeks up to 6 mg bid
  9. Cost
    1. (2003) Red Book: $130/month
  10. References
    1. (2000) Med Lett Drugs Ther 42(1089):93
    2. Corey-Bloom (1998) Int J Geriatr Psychopharm 1:55
    3. Rosler (1999) BMJ 318:633

rivastigmine (C0649350)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC072506
Englishrivastigmine, RIVASTIGMINE PREPARATION
Spanishrivastigmina
Parent ConceptsAcetylcholinesterase Inhibitors (C0001046), SDZ ENA 713 (C0141824), [CN900] CNS MEDICATIONS, OTHER (C0973511), Reversible anticholinesterase (C0304408), Central acetylcholinesterase inhibitor (C0594440), Antidementia agent (C1531592), Cholinesterase Inhibitors (C0008425)
SourcesMSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Exelon (C0730987)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC072506
EnglishExelon
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree